logo

CTKB

Cytek Biosciences·NASDAQ
--
--(--)
--
--(--)
9.60 / 10
Outperform

CTKB's fundamental assessment is superior at 9.6/10. Key strengths include a perfect Net profit attributable to parent company shareholders to Net profit ratio of 100%, robust EBIT to total operating revenue ratio, and favorable asset-to-market value and revenue-to-market value metrics. However, the company shows negative year-over-year revenue growth (-2.54%) and a low current assets turnover ratio (0.355), which limit its operational efficiency score. Overall, the fundamentals are very promising but not without execution risks related to growth and asset utilization.

Fundamental(9.6)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-0.29
Score2/3
Weight62.92%
1M Return3.00%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.00
Score2/3
Weight-28.77%
1M Return-1.63%
Total operating revenue (YoY growth rate %)
Value-2.54
Score1/3
Weight-39.41%
1M Return-2.56%
Net cash flow from operating activities / Operating revenue (%)
Value-2.81
Score2/3
Weight18.34%
1M Return0.98%
Net income-Revenue
Value-0.17
Score1/3
Weight-12.84%
1M Return-0.69%
Net profit margin (%)
Value-16.12
Score2/3
Weight17.32%
1M Return0.90%
Current assets turnover ratio
Value0.36
Score0/3
Weight-87.56%
1M Return-7.31%
EBIT / Total operating revenue (%)
Value-18.84
Score2/3
Weight21.55%
1M Return1.12%
Asset-MV
Value-0.50
Score3/3
Weight127.72%
1M Return5.62%
Net profit / Total operating revenue (%)
Value-16.12
Score2/3
Weight20.73%
1M Return1.07%
Is CTKB fundamentally strong?
  • CTKB scores 9.60/10 on fundamentals and holds a Discounted valuation at present. Backed by its -5.80% ROE, -6.51% net margin, -89.28 P/E ratio, 1.51 P/B ratio, and -37.50% earnings growth, these metrics solidify its Outperform investment rating.